CINCINNATI--(BUSINESS WIRE)--Symplmed Pharmaceuticals announced today that it has entered into an agreement with VAYA Pharma to distribute its medical food products – Vayarin®, Vayacog® and Vayarol® – through VAYA-Direct. The patient membership program, powered by Symplmed’s patented DyrctAxess technology, will provide prescribers and patients with a guaranteed price of $49.50 or less for each of VAYA’s products at the recommended daily dose as prescribed by physicians. VAYA-Direct will also accept insurance plans and provide delivery right to a patient’s home, as well as prompt refills.
“Partnering with VAYA Pharma to improve patient access to medications for chronic diseases through our DyrctAxess platform is validation of our technology and the support patients need to adhere to and fulfill their prescriptions,” said Erik Emerson, President and CEO of Symplmed Pharmaceuticals. “VAYA has an acute understanding of the business opportunities created by managing the prescription fulfillment activity for a patient, which is the fundamental concept of DyrctAxess.”
Symplmed and VAYA conducted a pilot during the second and third quarters of 2014 to evaluate operational implementation and patient acceptance. Upon completion of the pilot, it was clear that a strong patient need existed and that Symplmed’s DyrctAxess platform was fulfilling that need operationally.
“During the brief pilot phase with Symplmed, we learned a great deal about fulfillment habits and other various distribution insights that we can now implement to provide a better solution for both patients and prescribers,” said Yonatan Manor, Chief Operating Officer, VAYA Pharma. “We look forward to working with Symplmed to continue to meet the healthcare needs of patients who rely on medical food for disease management.”
VAYA-Direct is the second program to use the DyrctAxess technology to streamline the prescription process. bpCareConnect, owned by Symplmed, is a patient membership program that caps blood pressure medication costs, provides monitoring devices, offers online tracking tools and ships directly to the patient. Through the secure portal, patients can communicate treatment response data to prescribing physicians between office visits. Additionally, if approved by the U.S. Food and Drug Administration (FDA), Symplmed plans to offer Prestalia® (perindopril/amlodipine) through bpCareConnect.
About Symplmed
Symplmed Pharmaceuticals is a private pharmaceutical company optimizing the value of its medicines and those of its industry partners by streamlining the prescription process, from fulfillment and payment to therapeutic compliance and outcomes monitoring. The Company’s patented technology platform, DyrctAxess, enables direct delivery of medications to a patient’s home and addresses the problem of unfilled prescriptions. Symplmed is taking a therapeutic area approach, ensuring that medications necessary to manage a particular disease state are available through its DyrctAxess platform. The Company’s initial focus is high blood pressure (hypertension) with a proprietary ACE inhibitor ACEON® (perindopril erbumine) and Prestalia®, a single-pill, fixed-dose combination (FDC) of perindopril arginine and amlodipine besylate that is currently under review by the FDA. Symplmed also plans to expand its pipeline in multiple therapeutic areas. For more information, visit www.symplmed.com.
About VAYA Pharma
VAYA Pharma is a specialty pharmaceutical division of Enzymotec Ltd. (Nasdaq: ENZY) dedicated to the discovery, development, manufacture and marketing of innovative proprietary clinically tested lipid-based compositions familiar to the human body for addressing disorders that are impacted by lipid imbalances. VAYA Pharma’s medical food portfolio addresses three therapeutic segments: ADHD (Vayarin®), Early Memory Impairment (Vayacog®) and Hypertriglyceridemia (Vayarol®). Patients can access the benefits of Vayarin via www.vayarin.com and clicking on the “order button.” VAYA Pharma products are available in the U.S. only by prescription under the supervision of a physician. VAYA Pharma USA is headquartered in Greenville, South Carolina. For more information, visit www.vayapharma.com.
Forward-Looking Statement
All of the statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which Symplmed does business, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements.